Johns Hopkins trained physicians create start-up to produce cheap generic drugs

NewsGuard 100/100 Score

A group of Johns Hopkins trained physicians has started a crowdfunding campaign to create a start-up which produces cheap generic drugs (campaign web site: www.igg.me/at/cheapdrugs).

The campaign comes in response to recent dramatic increases in the prices of generic pharmaceuticals. For example, the price of Daraprim, a drug used to fight an AIDS related infection, has increased in cost from $13.50 a pill to $750 after rights to the drug were acquired by Turing Pharmaceuticals.

"We are increasingly frustrated by outrageous increases in the prices of generic pharmaceuticals and artificial shortages of common drugs," says founder Alexander Oshmyansky, MD, PhD. "It is affecting the healthcare we can provide and endangering patient lives here in the US.

"Our campaign seeks to raise $1M to perform the necessary early development towards building a pharmaceutical plant to create cheap generic pharmaceuticals. We need people to help us in this fight."

The group of physicians intends to create a public service B Corporation, "Cheap Drugs, Inc.," with the intention of producing affordable generic pharmaceuticals again.

Source:

Cheap Drugs, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show